This trial will study whether using PSMA PET/CT to guide treatment for high-risk prostate cancer results in better outcomes than using conventional imaging.
1 Primary · 6 Secondary · Reporting Duration: 5 years
Active Control
Experimental Treatment
776 Total Participants · 2 Treatment Groups
Primary Treatment: PSMA PET/CT guided intensification of therapy · No Placebo Group · Phase 3
Age 18+ · Male Participants · 6 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:New York | 100.0% |
London Health Sciences Centre | 100.0% |
Met criteria | 100.0% |
0 | 100.0% |